Lin and colleagues found that Raloxifene, a selective estrogen receptor modulator which was approved for reducing the risk of invasive breast cancer, attenuates STAT3 phosphorylation and transcriptional activity via inhibiting IL-6/GP130 interaction in various cancer (including breast cancer) cell lines (Shi et al., 2017), suggesting that this inhibitor may work by influencing numerous critical pathways in hormone positive breast cancer cells. Here, ESR1 is linked to breast carcinoma.